Natural Cycles is in talks to raise more than $55 million to scale its hormone-free birth control solution, as per reports. The app, scientifically validated to track basal body temperature, helps women accurately identify fertile days, offering a trusted, non-hormonal contraceptive option.
This new funding round, driven by strong investor interest including Lauxera Capital Partners, aims to enhance the platform’s infrastructure, especially by automating healthcare reimbursement processes, to improve accessibility and user experience globally.
Founded in 2013 by physicist Dr Elina Berglund Scherwitzl and her partner Dr Raoul Scherwitzl, the company’s mission is to democratize women’s health by providing safe, natural contraceptive alternatives. Their vision is a world where every woman has access to effective, hormone-free birth control through advanced technology.
Natural Cycles stands apart as the first digital contraception app with FDA clearance and other regulatory approvals worldwide. Its patented temperature-based algorithm personalises fertility tracking with clinical accuracy, distinguishing it from basic period trackers and hormonal contraceptives.
Women use the app to navigate fertility with a daily fertility status: “green days” safe for unprotected sex and “red days” signalling fertility risk requiring protection.
The company operates in a competitive landscape of digital contraception and fertility tracking apps, alongside notable players such as Clue, Flo, AvaWomen, and Inne.io. What sets Natural Cycles apart is its status as the first FDA-cleared, CE-marked digital contraceptive app with clinical validation supporting its patented algorithm that uses basal body temperature data to predict fertile days accurately.
Looking forward, Natural Cycles plans to use the funds to accelerate international expansion, deepen integration with healthcare reimbursement systems to streamline costs for users, and broaden its product suite.
